Nanomatrix Coated Stent Enhances Endothelialization but Reduces Platelet, Smooth Muscle Cell, and Monocyte Adhesion under Physiologic Conditions

G. C. Alexander; P. T.J. Hwang; J. Chen; J. Kim; B. C. Brott; Y. S. Yoon; H. W. Jun

doi:10.1021/acsbiomaterials.7b00676

Nanomatrix Coated Stent Enhances Endothelialization but Reduces Platelet, Smooth Muscle Cell, and Monocyte Adhesion under Physiologic Conditions

G. C. Alexander, P. T.J. Hwang, J. Chen, J. Kim, B. C. Brott, Y. S. Yoon, H. W. Jun

BioMedical Science Institute

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Cardiovascular disease is presently the number one cause of death worldwide. Current stents used to treat cardiovascular disease have a litany of unacceptable shortcomings: adverse clinical events include restenosis, neointimal hyperplasia, thrombosis, inflammation, and poor re-endothelialization. We have developed a biocompatible, multifunctional, peptide amphiphile-based nanomatrix coating for stents. In this study, we evaluated the ability of the nanomatrix coated stent to simultaneously address the issues facing current stents under physiological flow conditions in vitro. We found that the nanomatrix coated stent could increase endothelial cell migration, adhesion, and proliferation (potential for re-endothelialization), discourage smooth muscle cell migration and adhesion (potential to reduce neointimal hyperplasia and restenosis), and decrease both platelet activation and adhesion (potential to prevent thrombosis) as well as monocyte adhesion (potential to attenuate inflammatory responses) under physiological flow conditions in vitro. These promising results demonstrate the potential clinical utility of this nanomatrix stent coating, and highlight the importance of biocompatibility, multifunctionality, and bioactivity in cardiovascular device design.

Original language	English
Pages (from-to)	107-115
Number of pages	9
Journal	ACS Biomaterials Science and Engineering
Volume	4
Issue number	1
DOIs	https://doi.org/10.1021/acsbiomaterials.7b00676
Publication status	Published - 2018 Jan 8

Bibliographical note

Funding Information:
This study was supported by NIH T-32 Cardiovascular Pathophysiology Training Fellowship (5T32HL007918-17 to G.A.), Alabama EPSCoR GRSP Fellowship (to G.A.), NIH (1R01HL125391, 1R43NS095455, 1R43DK109789, 2R44DK109789-02 to H.J.), NIH (R01HL127759, 1DP3DK108245, R01HL129511 to Y.Y. and H.J.), NIH (1R01HL128695 to J.K.), and in part by a grant to the University of Alabama at Birmingham from the Howard Hughes Medical Institute through the Med into Grad Initiative.

Publisher Copyright:
© 2017 American Chemical Society.

All Science Journal Classification (ASJC) codes

Biomaterials
Biomedical Engineering

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1021/acsbiomaterials.7b00676

Fingerprint Dive into the research topics of 'Nanomatrix Coated Stent Enhances Endothelialization but Reduces Platelet, Smooth Muscle Cell, and Monocyte Adhesion under Physiologic Conditions'. Together they form a unique fingerprint.

Cite this

@article{dd93a4c64b0b4c44a9cce79394640e8a,

title = "Nanomatrix Coated Stent Enhances Endothelialization but Reduces Platelet, Smooth Muscle Cell, and Monocyte Adhesion under Physiologic Conditions",

abstract = "Cardiovascular disease is presently the number one cause of death worldwide. Current stents used to treat cardiovascular disease have a litany of unacceptable shortcomings: adverse clinical events include restenosis, neointimal hyperplasia, thrombosis, inflammation, and poor re-endothelialization. We have developed a biocompatible, multifunctional, peptide amphiphile-based nanomatrix coating for stents. In this study, we evaluated the ability of the nanomatrix coated stent to simultaneously address the issues facing current stents under physiological flow conditions in vitro. We found that the nanomatrix coated stent could increase endothelial cell migration, adhesion, and proliferation (potential for re-endothelialization), discourage smooth muscle cell migration and adhesion (potential to reduce neointimal hyperplasia and restenosis), and decrease both platelet activation and adhesion (potential to prevent thrombosis) as well as monocyte adhesion (potential to attenuate inflammatory responses) under physiological flow conditions in vitro. These promising results demonstrate the potential clinical utility of this nanomatrix stent coating, and highlight the importance of biocompatibility, multifunctionality, and bioactivity in cardiovascular device design.",

author = "Alexander, {G. C.} and Hwang, {P. T.J.} and J. Chen and J. Kim and Brott, {B. C.} and Yoon, {Y. S.} and Jun, {H. W.}",

note = "Funding Information: This study was supported by NIH T-32 Cardiovascular Pathophysiology Training Fellowship (5T32HL007918-17 to G.A.), Alabama EPSCoR GRSP Fellowship (to G.A.), NIH (1R01HL125391, 1R43NS095455, 1R43DK109789, 2R44DK109789-02 to H.J.), NIH (R01HL127759, 1DP3DK108245, R01HL129511 to Y.Y. and H.J.), NIH (1R01HL128695 to J.K.), and in part by a grant to the University of Alabama at Birmingham from the Howard Hughes Medical Institute through the Med into Grad Initiative. Publisher Copyright: {\textcopyright} 2017 American Chemical Society.",

year = "2018",

month = jan,

day = "8",

doi = "10.1021/acsbiomaterials.7b00676",

language = "English",

volume = "4",

pages = "107--115",

journal = "ACS Biomaterials Science and Engineering",

issn = "2373-9878",

publisher = "American Chemical Society",

number = "1",

}

Nanomatrix Coated Stent Enhances Endothelialization but Reduces Platelet, Smooth Muscle Cell, and Monocyte Adhesion under Physiologic Conditions. / Alexander, G. C.; Hwang, P. T.J.; Chen, J.; Kim, J.; Brott, B. C.; Yoon, Y. S.; Jun, H. W.

In: ACS Biomaterials Science and Engineering, Vol. 4, No. 1, 08.01.2018, p. 107-115.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Nanomatrix Coated Stent Enhances Endothelialization but Reduces Platelet, Smooth Muscle Cell, and Monocyte Adhesion under Physiologic Conditions

AU - Alexander, G. C.

AU - Hwang, P. T.J.

AU - Chen, J.

AU - Kim, J.

AU - Brott, B. C.

AU - Yoon, Y. S.

AU - Jun, H. W.

N1 - Funding Information: This study was supported by NIH T-32 Cardiovascular Pathophysiology Training Fellowship (5T32HL007918-17 to G.A.), Alabama EPSCoR GRSP Fellowship (to G.A.), NIH (1R01HL125391, 1R43NS095455, 1R43DK109789, 2R44DK109789-02 to H.J.), NIH (R01HL127759, 1DP3DK108245, R01HL129511 to Y.Y. and H.J.), NIH (1R01HL128695 to J.K.), and in part by a grant to the University of Alabama at Birmingham from the Howard Hughes Medical Institute through the Med into Grad Initiative. Publisher Copyright: © 2017 American Chemical Society.

PY - 2018/1/8

Y1 - 2018/1/8

N2 - Cardiovascular disease is presently the number one cause of death worldwide. Current stents used to treat cardiovascular disease have a litany of unacceptable shortcomings: adverse clinical events include restenosis, neointimal hyperplasia, thrombosis, inflammation, and poor re-endothelialization. We have developed a biocompatible, multifunctional, peptide amphiphile-based nanomatrix coating for stents. In this study, we evaluated the ability of the nanomatrix coated stent to simultaneously address the issues facing current stents under physiological flow conditions in vitro. We found that the nanomatrix coated stent could increase endothelial cell migration, adhesion, and proliferation (potential for re-endothelialization), discourage smooth muscle cell migration and adhesion (potential to reduce neointimal hyperplasia and restenosis), and decrease both platelet activation and adhesion (potential to prevent thrombosis) as well as monocyte adhesion (potential to attenuate inflammatory responses) under physiological flow conditions in vitro. These promising results demonstrate the potential clinical utility of this nanomatrix stent coating, and highlight the importance of biocompatibility, multifunctionality, and bioactivity in cardiovascular device design.

AB - Cardiovascular disease is presently the number one cause of death worldwide. Current stents used to treat cardiovascular disease have a litany of unacceptable shortcomings: adverse clinical events include restenosis, neointimal hyperplasia, thrombosis, inflammation, and poor re-endothelialization. We have developed a biocompatible, multifunctional, peptide amphiphile-based nanomatrix coating for stents. In this study, we evaluated the ability of the nanomatrix coated stent to simultaneously address the issues facing current stents under physiological flow conditions in vitro. We found that the nanomatrix coated stent could increase endothelial cell migration, adhesion, and proliferation (potential for re-endothelialization), discourage smooth muscle cell migration and adhesion (potential to reduce neointimal hyperplasia and restenosis), and decrease both platelet activation and adhesion (potential to prevent thrombosis) as well as monocyte adhesion (potential to attenuate inflammatory responses) under physiological flow conditions in vitro. These promising results demonstrate the potential clinical utility of this nanomatrix stent coating, and highlight the importance of biocompatibility, multifunctionality, and bioactivity in cardiovascular device design.

UR - http://www.scopus.com/inward/record.url?scp=85037849893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037849893&partnerID=8YFLogxK

U2 - 10.1021/acsbiomaterials.7b00676

DO - 10.1021/acsbiomaterials.7b00676

M3 - Article

AN - SCOPUS:85037849893

VL - 4

SP - 107

EP - 115

JO - ACS Biomaterials Science and Engineering

JF - ACS Biomaterials Science and Engineering

SN - 2373-9878

IS - 1

ER -

Nanomatrix Coated Stent Enhances Endothelialization but Reduces Platelet, Smooth Muscle Cell, and Monocyte Adhesion under Physiologic Conditions

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this